HBED: The continuing development of a potential alternative to deferoxamine for iron-chelating therapy

被引:37
作者
Bergeron, RJ
Wiegand, J
Brittenham, GM
机构
[1] Univ Florida, J Hillis Miller Hlth Ctr, Dept Med Chem, Gainesville, FL 32610 USA
[2] Case Western Reserve Univ, Metrohlth Med Ctr, Dept Med, Cleveland, OH USA
关键词
D O I
10.1182/blood.V93.1.370.401k29_370_375
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To further examine the potential clinical usefulness of the hexadentate phenolic aminocarboxylate iron chelator N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED) for the chronic treatment of transfusional iron overload, we performed a subchronic toxicity study of the HEED monosodium salt in rodents and have evaluated the iron excretion in primates induced by HEED. The HEED-induced iron excretion was determined for the monohydrochloride dihydrate that was first dissolved in a 0.1-mmol/L sodium phosphate buffer at pH 7.6 and administered to the primates either orally (PO) at a dose of 324 mu mol/kg (149.3 mg/kg, n = 5), subcutaneously (sc) at a dose of 81 mu mol/kg (37.3 mg/kg, n = 5), sc at 324 mu mol/kg (n = 5), and sc at 162 mu mol/kg (74.7 mg/kg) for 2 consecutive days for a total dose of 324 mu mol/kg (n = 3). In addition, the monosodium salt of HEED in saline was administered to the monkeys sc at a single dose of 150 mu mol/kg (64.9 mg/kg, n = 5) or at a dose of 75 mu mol/kg every other day for three doses, for a total dose of 225 mu mol/kg (n = 4). For comparative purposes, we have also administered deferoxamine (DFO) PO and sc in aqueous solution at a dose of 300 mu mol/kg (200 mg/kg). In the iron-loaded Cebus apella monkey, whereas the PO administration of DFO or HEED even at a dose of 300 to 324 mu mol/kg was ineffective, the sc injection of HEED in buffer or its monosodium salt, 75 to 324 mu mol/kg, produced a net iron excretion that was nearly three times that observed after similar doses of sc DFO. In patients with transfusional iron overload, sc injections of HEED may provide a much needed alternative to the use of prolonged parenteral infusions of DFO. Note: After the publication of our previous paper (Blood, 91:1446, 1998) and the completion of the studies described here, it was discovered that the HEED obtained from Strem Chemical Co (Newburyport, MA) that was labeled and sold as a dihydrochloride dihydrate was in fact the monohydrochloride dihydrate. Therefore, the actual administered doses were 81, 162, or 324 mu mol/kg; not 75, 150, or 300 mu mol/kg as was previously reported. The new data have been recalculated accordingly, and the data from our earlier study; corrected where applicable, are shown in parentheses. (C) 1999 by The American Society of Hematology.
引用
收藏
页码:370 / 375
页数:6
相关论文
共 38 条
[1]  
ATHANASIOU A, 1981, LANCET, V2, P616
[2]  
BERGERON RJ, 1990, ANN NY ACAD SCI, V612, P378
[3]  
BERGERON RJ, 1993, BLOOD, V82, P2552
[4]  
BERGERON RJ, 1993, BLOOD, V81, P2166
[5]  
BERGERON RJ, 1992, BLOOD, V79, P1882
[6]   HBED: A potential alternative to deferoxamine for iron-chelating therapy [J].
Bergeron, RJ ;
Wiegand, J ;
Brittenham, GM .
BLOOD, 1998, 91 (04) :1446-1452
[7]   STOFFWECHSELPRODUKTE VON ACTINOMYCETEN .27. UBER DIE KONSTITUTION VON FERRIOXAMIN-B [J].
BICKEL, H ;
HALL, GE ;
KELLERSCHIERLEIN, W ;
PRELOG, V ;
VISCHER, E ;
WETTSTEIN, A .
HELVETICA CHIMICA ACTA, 1960, 43 (07) :2129-2138
[8]   DEFEROXAMINE-INDUCED BONE DYSPLASIA IN PATIENTS WITH THALASSEMIA MAJOR [J].
BRILL, PW ;
WINCHESTER, P ;
GIARDINA, PJ ;
CUNNINGHAMRUNDLES, S .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1991, 156 (03) :561-565
[9]  
BRITTENHAM GM, 1990, SEMIN HEMATOL, V27, P112
[10]   EFFICACY OF DEFEROXAMINE IN PREVENTING COMPLICATIONS OF IRON OVERLOAD IN PATIENTS WITH THALASSEMIA MAJOR [J].
BRITTENHAM, GM ;
GRIFFITH, PM ;
NIENHUIS, AW ;
MCLAREN, CE ;
YOUNG, NS ;
TUCKER, EE ;
ALLEN, CJ ;
FARRELL, DE ;
HARRIS, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (09) :567-573